Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (PL)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 1, January-February, p. 165–171

Publication type: review article

Language: Polish

Hiperlipidemie u dzieci

Hyperlipidemias in Children

Michał Grabiński1,

1 II Katedra i Klinika Pediatrii, Gastroenterologii i Żywienia

Streszczenie

Choroba niedokrwienna serca oraz inne choroby układu krążenia o podłożu miażdżycowym są główną przyczyną zgonów wśród dorosłej populacji w wielu krajach. Badania wykazały, że proces miażdżycowy zaczyna się już w dzieciństwie, a zaburzenia gospodarki lipidowej są jednym z głównych czynników ryzyka jego rozwoju. W pracy przedstawiono podział, obraz kliniczny, zasady rozpoznawania oraz leczenia najczęścej występujących hiperlipidemii u dzieci.

Abstract

Coronary heart disease and other atherosclerotic cardiovascular diseases are the leading cause of death in adult populations of many countries. Studies have shown, that atherosclerosis begins in childhood and disorders of lipid metabolism are one of the major risk factors. In this article, the classification, clinical picture, diagnostic procedures and treatment in most common hyperlipidemias in pediatric population are presented.

Słowa kluczowe

hiperlipidemie, klasyfikacja, obraz kliniczny, rozpoznawanie, leczenie, dzieci

Key words

hyperlipidemia, classification, clinical picture, diagnosis, treatment, children

References (35)

  1. Herold G: Medycyna wewnętrzna. PZWL, Warszawa 2001.
  2. Garanty−Bogacka B, Syrenicz M, Syrenicz A, Walczak M: Hiperlipidemie u dzieci i młodzieży. Klin Pediat 2002, 10, 459–471.
  3. Tatoń J: Miażdżyca – zapobieganie w praktyce lekarskiej. PZWL, Warszawa 2000.
  4. Czech A, Tatoń J, Walewski J: Diagnostyka i algorytmy leczenia dyslipidemii u osób z cukrzycą typu 2. Terapia 2004, 3, 59–64.
  5. Cybulska B: Wykrywanie, ocena i leczenie hipercholesterolemii u dorosłych – cz. IV. III Raport Zespołu Ekspertów National Cholesterol Education Program (USA) wg Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) National Heart, Lung, and Blood Institute National Institutes of Health. NIH Publication No. 02−5215, September 2002. Med Prakt 2003, 6, 65–83.
  6. Clauss SB, Kwiterovich PO: Genetic disorders of lipoprotein transport in children. Prog Pediatr Cardiol 2003, 17, 123–133.
  7. Iwańczak F, Śmigiel R: Najczęstsze wrodzone genetycznie uwarunkowane zaburzenia przemiany białkowej i lipidowej u dzieci. Gastroenterol Pol 2004, 11, 375–383.
  8. Zschocke J, Hoffmann G: Vademecum Metabolicum. Milupa GmbH, Heidelberg 1999.
  9. Gagnon F, Jarvik GP, Badzioch MD, Motulsky AG, Brunzell JD, Wijsman EM: Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia. Hum Genet 2005, 117, 494–505.
  10. Freedman DS, Dietz WH: The relation of overweight to cardiovascular risc factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999, 103, 1175–1182.
  11. Wiegman A, Sijbrands EJ: The apolipoprotein E4 allele confers additional risk in children with familial hypercholesterolemia. Pediat Res 2003, 53, 1008–1012.
  12. De Jongh S, Lilien MR, Roodt J, Stroes ESG, Bakker HD, Kastelein JJP: Early Statin Therapy Restores Endothelial Function in Children With Familial hypercholesterolemia. J Am Coll Cardiol 2002, 40, 2117–2121.
  13. De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG: Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002, 163, 193–197.
  14. Glowinska B, Urban M, Koput A, Galar M: Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes. Przegl Lek 2003, 60, 12–17.
  15. Wiegman A, Rodenburg J, de Jongh S, Defesche JC, Bakker HD, KasteleinJJP, Sijbrands EJG: Family History and Cardiovascular Risk in Familial Hypercholesterolemia. Data in More Than 1000 Children. Circulation 2003, 107, 1473–1478.
  16. Wiegman A, DeGroot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJG, Kastelein JJP: Arterial intima−media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004, 363, 369–370.
  17. Lesauskaite V, Stalioraityte E, Tanganelli P, Epistolato MC: Pathobiological determinants of atherosclerosis in youths: data from a macromorphometric and histomorphometric investigation of the aorta and coronary arteries. Medicina (Kaunas) 2004, 40, 633–637.
  18. McGill HC, McMahon A, Herderick EE, Malcom GT, Tracy RE, Strong JP: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000, 72 (Suppl), 1307S–1315S.
  19. Valente AM, Newburger JW, Lauer RM: Hyperlipidemia in children and adolescents. Am Heart J 2001, 142, 433–439.
  20. American Academy of Pediatrics:. National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992, 89, 525–584.
  21. Cybulska B, Szostak W: Profilaktyka choroby niedokrwiennej serca w praktyce internistycznej. Post Nauk Med 2001, 3–4, 3–10.
  22. Radomyska B: Badania przesiewowe populacji wieku rozwojowego w kierunku hiperlipidemii w aspekcie profilaktyki miażdżycowej. Med Wieku Rozw 2001, 5, 27–34.
  23. Couch SC, Daniels SR, Deckelbaum RJ: Current concepts of diet therapy for children with hypercholesterolemia. Prog Pediatr Cardiol 2003, 17, 179–186.
  24. Shamir R, Fisher EA: Dietary therapy for children with hypercholesterolemia. Am Fam Physician 2000, 61, 675–682, 685–686.
  25. Williams CL, Bollella MC, Strobino BA, Boccia L, CampanaroL: Plant Stanol Ester and Bran Fiber in Childhood: Effects on Lipids, Stool Weight and Stool Frequency in Preschool Children. J Am Coll Nutr 1999, 18, 572–581.
  26. Sanchez−Bayle M, Gonzalez−Requejo A, Asensio−Anton J, Ruiz−Jarabo C, Fernandez−Ruiz M, Baeza J: The effect of fiber supplementation on lipid profile in children with hypercholesterolemia. Clin Pediatr 2001, 40, 291–294.
  27. Kronn DF, Sapru A, Satou GM: Management of hypercholesterolemia in childhood and adolescence. Heart Dis 2000, 2, 348–353.
  28. Tonstad S: Role of lipid−lowering pharmacotherapy in children. Pediatric Drugs 2000, 2(1), 11–22.
  29. Tonstad S, Thompson GR: Management of Hyperlipidemia in the Pediatric Population. Curr Treat Options Cardiovasc Med 2004, 6, 431–437.
  30. McCrindle BW, Ose L, Marais AD: Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo−controlled trial. J Pediatr 2003, 142, 74–80.
  31. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. J Am Med Assoc 2004, 292, 331–337.
  32. Gibb H, Scialli AR: Statin drugs and congenital anomalies. Am J Med Genet 2004 15, 131, 287–298.
  33. Burnett JR, Ravine D, van Bockxmeer FM, Watts GF: Familial hypercholesterolaemia: a look back, a look ahead: Med J Aust 2005, 182, 552–553.
  34. Naoumova RP, Thompson GR, Soutar AK: Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004, 15, 413–422.
  35. Daniels SR: Cholesterol abnormalities in children and adolescents: time for an update of the 1992 National Cholesterol Education Program guidelines. Prog Pediatr Cardiol 2003, 17, 109–111.
© Wroclaw Medical University